BioHarvest Sciences to Participate in 37th Annual Roth Conference on March 16-18, 2025
BioHarvest Sciences (NASDAQ: BHST) has announced its participation in the 37th Annual Roth Conference, scheduled for March 16-18, 2025, at the Laguna Cliffs Marriott Resort & Spa in Dana Point, CA. CEO Ilan Sobel will conduct one-on-one meetings with institutional investors throughout the event.
The company, which pioneers the patented Botanical Synthesis technology platform, views this as a significant opportunity to showcase its growth trajectory. Following their Nasdaq listing and the launch of their CDMO Services Division, BioHarvest has achieved notable milestones, including:
- VINIA product reaching $50 Million in cumulative sales
- Advancement in CDMO Services division research for plant-based solutions
- Partnerships with pharmaceutical, nutraceutical, cosmetics, and nutrition sectors
BioHarvest Sciences (NASDAQ: BHST) ha annunciato la sua partecipazione al 37° Annual Roth Conference, previsto per il 16-18 marzo 2025, presso il Laguna Cliffs Marriott Resort & Spa a Dana Point, CA. Il CEO Ilan Sobel condurrà incontri individuali con investitori istituzionali durante l'evento.
L'azienda, che è pioniera della piattaforma tecnologica brevettata Botanical Synthesis, considera questa un'opportunità significativa per mettere in mostra la sua traiettoria di crescita. Dopo la loro quotazione al Nasdaq e il lancio della Divisione Servizi CDMO, BioHarvest ha raggiunto traguardi notevoli, tra cui:
- Il prodotto VINIA ha raggiunto $50 milioni di vendite cumulative
- Avanzamenti nella ricerca della divisione Servizi CDMO per soluzioni vegetali
- Partnership con i settori farmaceutico, nutraceutico, cosmetico e della nutrizione
BioHarvest Sciences (NASDAQ: BHST) ha anunciado su participación en la 37ª Conferencia Anual Roth, programada para el 16-18 de marzo de 2025, en el Laguna Cliffs Marriott Resort & Spa en Dana Point, CA. El CEO Ilan Sobel llevará a cabo reuniones individuales con inversores institucionales durante el evento.
La empresa, que es pionera en la plataforma tecnológica patentada Botanical Synthesis, ve esto como una oportunidad significativa para mostrar su trayectoria de crecimiento. Tras su listado en Nasdaq y el lanzamiento de su División de Servicios CDMO, BioHarvest ha logrado hitos notables, incluyendo:
- El producto VINIA alcanzando $50 millones en ventas acumuladas
- Avances en la investigación de la división de Servicios CDMO para soluciones basadas en plantas
- Asociaciones con los sectores farmacéutico, nutracéutico, cosmético y de nutrición
BioHarvest Sciences (NASDAQ: BHST)는 2025년 3월 16일부터 18일까지 캘리포니아 다나 포인트에 위치한 라구나 클리프스 메리어트 리조트 & 스파에서 열리는 제37회 연례 로스 컨퍼런스에 참여한다고 발표했습니다. CEO 일란 소벨은 행사 기간 동안 기관 투자자들과 일대일 미팅을 진행할 예정입니다.
특허받은 Botanical Synthesis 기술 플랫폼의 선구자인 이 회사는 성장 궤적을 보여줄 수 있는 중요한 기회로 보고 있습니다. 나스닥 상장과 CDMO 서비스 부서 출범 이후, BioHarvest는 다음과 같은 주목할 만한 이정표를 달성했습니다:
- VINIA 제품이 누적 매출 5천만 달러에 도달
- 식물 기반 솔루션을 위한 CDMO 서비스 부서 연구의 진전
- 제약, 영양제, 화장품 및 영양 분야와의 파트너십
BioHarvest Sciences (NASDAQ: BHST) a annoncé sa participation à la 37ème Conférence Annuelle Roth, prévue du 16 au 18 mars 2025, au Laguna Cliffs Marriott Resort & Spa à Dana Point, Californie. Le PDG Ilan Sobel tiendra des réunions individuelles avec des investisseurs institutionnels tout au long de l'événement.
L'entreprise, qui est pionnière de la plateforme technologique brevetée Botanical Synthesis, considère cela comme une opportunité significative de mettre en avant sa trajectoire de croissance. Suite à leur inscription au Nasdaq et au lancement de leur Division des Services CDMO, BioHarvest a atteint des jalons notables, notamment :
- Le produit VINIA ayant atteint 50 millions de dollars de ventes cumulées
- Avancées dans la recherche de la division des Services CDMO pour des solutions à base de plantes
- Partenariats avec les secteurs pharmaceutique, nutraceutique, cosmétique et de la nutrition
BioHarvest Sciences (NASDAQ: BHST) hat seine Teilnahme an der 37. jährlichen Roth-Konferenz angekündigt, die vom 16. bis 18. März 2025 im Laguna Cliffs Marriott Resort & Spa in Dana Point, Kalifornien, stattfinden wird. CEO Ilan Sobel wird während der Veranstaltung Einzelgespräche mit institutionellen Investoren führen.
Das Unternehmen, das die patentierte Botanical Synthesis-Technologieplattform entwickelt hat, sieht dies als eine bedeutende Gelegenheit, seine Wachstumskurve zu präsentieren. Nach ihrer Nasdaq-Notierung und der Einführung der CDMO-Dienstleistungsabteilung hat BioHarvest bemerkenswerte Meilensteine erreicht, darunter:
- Das Produkt VINIA hat einen kumulierten Umsatz von 50 Millionen Dollar erreicht
- Fortschritte in der Forschung der CDMO-Dienstleistungsabteilung für pflanzenbasierte Lösungen
- Partnerschaften mit den Bereichen Pharmazie, Nutraceuticals, Kosmetik und Ernährung
- None.
- None.
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 6, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the 37th Annual Roth Conference taking place on March 16-18, 2025.
CEO Ilan Sobel is scheduled to host one-on-one meetings with institutional investors throughout the duration of the event.
37th Annual Roth Conference for Growth Companies
Date: March 16-18, 2025
Location: Laguna Cliffs Marriott Resort & Spa - Dana Point, CA
Format: 1x1s Meetings
Sobel said: "I am pleased to announce our invitation to the 37th Annual Roth Conference, which is a high-profile opportunity to showcase BioHarvest's transformative growth story. Following our recent Nasdaq listing and the launch of our CDMO Services Division last year, we are well positioned to execute on our mission to commercialize life-changing, plant-based compounds. These efforts have resulted in major milestones in our direct-to-consumer business, where we recently announced that VINIA had reached
Registration is mandatory for conference participation. For more information or to schedule a meeting with management, please contact MZ Group at BHST@mzgroup.us.
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
This press release may contain "forward-looking statements". "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and any other risks identified in other filings made by the Company with the Securities and Exchange Commission.
This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(949) 259-4987
BHST@mzgroup.us
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243529
FAQ
When and where is BioHarvest Sciences (BHST) presenting at the Roth Conference 2025?
What major sales milestone has BHST's VINIA product achieved?
What are the key business segments of BioHarvest Sciences (BHST)?
Which industries does BioHarvest's (BHST) CDMO Services Division serve?
What is the format of BHST's participation at the 2025 Roth Conference?
